This combination of 3 drugs is commonly used in the management of HIV infection. Stavudine and Lamivudine belong to the nucleoside analogue class of antiretroviral drugs. Nevirapine is an NNRTI.

Please Consult your health care professional for the dosage and take exactly as prescribed

This medicine should be administered only to patients who have received Stavudine+Lamivudine(Standard Doses) + Nevirapine (200 MG OD) for 2 weeks and have demonstrated adequate tolerability to Nevirapine. Severe life threatening skin reactions including fatal cases have occurred in patient treated with Nevirapine. Patients developing signs or symptoms of severe skin reactions or hypersensitivity reactions must discontinue Nevirapine as soon as possible. Some other side effects of Nevirapine are Toxic Epidermal Necrolysis, Stevens-Johnsons Syndrome, Hypersensitivity reactions, Organ Dysfunction.

This medication is contraindicated in patients with clinically significant hypersensitivity to any of the components contained in the formulation. This medication is also contra indicated in patients who are just initiating therapy with Nevirapine. These patients require a lead in dosing of Nevirapine 200 mg o.d., where as this formulation contains the maintainence dose of Nevirapine 200 mg b.d.

If you suspect an overdose call the emergency department or your doctor immediately.

Do not double dosage to make up for a missed one

Stavudine and Lamivudine act by terminating the growth of the DNA chain and inhibiting the reverse transcriptase of HIV and Nevirapine acts by directly inhibiting reverse transcriptase.

Store in a cool dry place.